Journal of Yeungnam Medical Science
- 제18권2호
- /
- Pages.226-238
- /
- 2001
- /
- 2799-8010(eISSN)
혈액 투석 환자에서 조혈 호르몬 치료 효과 향상에 대한 연구
A Study for Improvement of Erythropoietin Responsiveness in Hemodialysis Patients
-
Park, Jong-Won
(Department of Internal Medicine, College of Medicine, Yeungnam University) ;
-
Do, Jun-Yeung
(Department of Internal Medicine, College of Medicine, Yeungnam University) ;
- Yoon, Kyung-Woo (Department of Internal Medicine, College of Medicine, Yeungnam University)
- 투고 : 2001.11.15
- 심사 : 2001.12.18
- 발행 : 2001.12.30
초록
본 연구는 만성 신부전 환자의 빈혈 치료로 사용되는 EPO의 효과를 감소시키는 여러 원인을 조사하고 각각의 원인에 대한 적절한 치료를 함으로써 EPO의 치료 효과를 향상시키고자 2001년 4월 현재까지 영남대학교 의과대학 부속병원 인공 신장실에서 6개월 이상 혈액 투석중인 72명을 대상으로 전향적 연구를 시행하였다. 전체 대상군(n=72) 에서 IVAA 12주 치료와 철분 상태에 따른 IVAA 효과를 판정하여 가장 효과적인 기능성 철 결핍 군에게는 IVAA 치료를 8주 연장하였다. 혈중 알루미늄이 4
Background: Anemia in chronic renal failure plays an important role in increasing morbidity of dialysis patients. The causes of the anemia are multifactorial. With using of erythropoietin(EPO) most of uremia-induced anemia can be overcome. However, about 10% of renal failure patients shows EPO-resistant anemia. Hyporesponsiveness to EPO has been related to many factors: iron deficiency, aluminum intoxication, inflammations, malignancies and secondary hyperparathyroidism. So I evaluated the improvement of EPO responsiveness after correction of above several factors. Materials and Methods: Seventy-two patients on hemodialysis over 6 months were treated with intravenous ascorbic acid(IVAA, 300 mg t.i.w. for 12 weeks), After administration of IVAA for 12 weeks, patients were classified into several groups according to iron status, serum aluminum levels and i-PTH levels. Indivisualized treatments were performed: increased iron supplement for absolute iron deficiency, active vitamin D3 for secondary hyperparathyroidism and desferrioxamine(DFO, 5 mg/kg t.i.w.) for aluminum intoxication or hyperferritinemia. Results: 1) Result of IVAA therapy for 12 weeks on all patients(n=72). Hemoglobin levels at 2, 4, 6 week were significantly elevated compared to baseline, but those of hemoglobin at 8, 10, 12 week were not significantly different. 2) Result of IVAA therapy for 20 weeks on patients with 100